Seven months after Syncona threw a financial lifeline to struggling Freeline Therapeutics, the London-based investment firm is overseeing Freeline's acquisition of SwanBio to create a new entity called Spur Therapeutics. Spur will be 99% owned by Syncona and is set to have a valuation of around £104.7 million ($132.7 million), with Syncona committing $50 million to fund development of the company's pipeline. Source: Fierce Biotech 17/6/2024